Alok Tewari, MD, PhD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-5456

alok_tewari@dfci.harvard.edu

Dana-Farber Cancer Institute
Phone: (617) 632-5456

alok_tewari@dfci.harvard.edu

Alok Tewari, MD, PhD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

Instructor, Medicine, Harvard Medical School
Translational Investigator, Medical Oncology, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Developmental Therapeutics, Member
Prostate Cancer, Member

Research Abstract

I am a translational investigator and clinician focused on prostate and testicular cancer as well as phase 1 clinical trials. I focus on epigenomic and genomic mechanisms of drug resistance in cancer with an emphasis on leveraging patient samples to explore disease biology. The goal of these studies is to develop rational molecularly-guided therapeutic strategies to overcome therapeutic resistance.

Ravi P, Zhong C, Xie W, Kelly E, Whelpley B, Kuczmarski K, Beltran H, Kilbridge KL, King MT, McGregor BA, Morgans AK, Pomerantz M, Taplin ME, Tewari AK, Viswanathan SR, Wei XX, Anh Huynh M, Choudhury AD. Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate Cancer. Eur Urol Oncol 2024. PubMed
Boiarsky D, Tewari AK, Gulhan DC, Bakouny Z, Ananda G, Savignano H, Lakshminarayanan G, McClure HM, Silver R, Choueiri TK, Taplin ME, Park PJ, Berchuck JE. A panel-based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration-resistant prostate cancer. Prostate 2024. PubMed
Boiarsky D, Gulhan DC, Savignano H, Lakshminarayanan G, McClure HM, Silver R, Hirsch MS, Sholl LM, Choudhury AD, Ananda G, Park PJ, Tewari AK, Berchuck JE. A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer 2024; 22:558-568.e3. PubMed
Orme JJ, Taza F, De Sarkar N, Tewari AK, Arsalan Naqvi S, Riaz IB, Childs DS, Omar N, Adra N, Ashkar R, Cheng HH, Schweizer MT, Sokolova AO, Agarwal N, Barata P, Sartor O, Bastos D, Smaletz O, Berchuck JE, McClure H, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Mehra N, Nelson PS, Hwang J, Dehm SM, Shi Q, Fleischmann Z, Sokol ES, Elliott A, Huang H, Bryce A, Marshall CH, Antonarakis ES. Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. Eur Urol Oncol 2023. PubMed
D'Andrea V, Jason Qian Z, Yim K, Egan J, Magnani CJ, Feldman A, Salari K, Tewari A, Steele G, Mossanen M, Preston M, Chang SL, Clinton TN. Anticoagulation prophylaxis patterns following retroperitoneal lymph node dissection for testis cancer. Urol Oncol 2023. PubMed
Rosen DB, Ghosh A, Niemierko A, Beard CJ, Ravi P, Tewari A, Sweeney C, Lee RJ, Saylor P, Martin N, Efstathiou JA, Mouw K, Kamran SC. Clinical outcomes of de novo versus relapsed early metastatic testicular seminoma treated with contemporary radiation therapy. Int J Radiat Oncol Biol Phys 2023. PubMed
Tewari AK, Cheung ATM, Crowdis J, Conway JR, Camp SY, Wankowicz SA, Livitz DG, Park J, Lis RT, Bosma-Moody A, He MX, AlDubayan SH, Zhang Z, McKay RR, Leshchiner I, Brown M, Balk SP, Getz G, Taplin ME, Van Allen EM. Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer. Cell Rep 2021; 36:109665. PubMed

Alok Tewari, MD, PhD

Dana-Farber Cancer Institute

Similar Members

Similar Members

Alok Tewari, MD, PhD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

DF/HCC PROGRAM AFFILIATION

Research Abstract

Publications from Harvard Catalyst Profiles

Similar Members

Similar Members